ALX Oncology ALXO

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.27 (-20.57%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of ALX Oncology (ALXO)
    ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $1.06

    • Market Cap

      $56.59 Million

    • Price-Earnings Ratio

      -0.41

    • Total Outstanding Shares

      52.74 Million Shares

    • Total Employees

      80

    • Dividend

      No dividend

    • IPO Date

      July 17, 2020

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      323 allerton avenue, South san francisco, CA, 94080

    • Homepage

      https://www.alxoncology.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities, Continuing$86.26 Million
    Net Cash Flow From Operating Activities, Continuing$-121.91 Million
    Net Cash Flow From Financing Activities$30.82 Million
    Net Cash Flow From Financing Activities, Continuing$30.82 Million
    Net Cash Flow From Operating Activities$-121.91 Million
    Net Cash Flow, Continuing$-4.84 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Depreciation and Amortization$900,000
    Interest Expense, Operating$1.73 Million
    Preferred Stock Dividends And Other Adjustments$0
    Diluted Earnings Per Share$-2.58
    Research and Development$116.37 Million
    Net Income/Loss$-134.85 Million

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Other Comprehensive Income/Loss$19,000
    Comprehensive Income/Loss Attributable To Parent$-134.83 Million
    Comprehensive Income/Loss$-134.83 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Equity$113.62 Million
    Equity Attributable To Parent$113.62 Million
    Liabilities And Equity$147.78 Million
    Assets$147.78 Million
    Other Non-current Assets$10.52 Million
    Accounts Payable$4.50 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ALXO from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.